Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study

2019; Elsevier BV; Volume: 44; Linguagem: Inglês

10.1016/j.breast.2019.01.008

1532-3080

Sérgio D. Simon, José Bines, Gustavo Werutsky, João Soares Nunes, Fernando Chalu Pacheco, J. G. M. Segalla, Andrea J.S. Gomes, Brigitte Marie H.R. Adam Van Eyll, Daniel Luiz Gimenes, Susanne Crocamo, Ruffo Freitas‐Júnior, Lissandra Dal Lago, Geraldo Silva Queiroz, Sérgio Jobim Azevedo, Daniela Dornelles Rosa, G. Delgado, Giuliano Santos Borges, Yeni Verônica do Nascimento, Facundo Zaffaroni, Jeovany Martínez-Mesa, Carlos H. Barrios,

Global Cancer Incidence and Screening

To describe stage I-III breast cancer (BC) molecular subtypes and outcomes among a cohort of patients from Brazil.AMAZONA study is a retrospective cohort conducted from June 2008 to January 2009 including women of at least 18 years old, with histologically proven breast cancer, diagnosed in 2001 (n = 2198) and 2006 (n = 2714). In this analysis, we included patients who underwent surgery, had stage I-III disease and available pathological information (n = 2296). We estimated molecular subtypes by local immunohistochemical stains. Data was obtained from medical charts and public databases.Mean age at diagnosis was 54 years and 41.1% were younger than 50 years. 23.3% were diagnosed in stage I, 53.5% in stage II and 23.2% in stage III. 80.8% were treated in the public health system. 71.3% had hormonal receptor positive disease, 15.7% were HER-2 positive and 21.1% had triple-negative breast cancer. 55.6% were treated with mastectomy and 96.2% received adjuvant treatment (82.2% chemotherapy). 13.4% of HER-2 positive patients received adjuvant trastuzumab. Overall survival rate at 5 years was 96.84% for stage I, 94.16% for stage II and 70.48% for stage III. Molecular subtypes were independent prognostic factor in stages II and III patients.Brazilian women have a higher risk of being diagnosed with late stage breast cancer and younger age than in high-income countries. Luminal-like disease is the most common molecular subtype in the country. Triple negative and HER-2 positive had the worst prognosis.